New drug aims to stop immune system from attacking transplanted livers
NCT ID NCT06455280
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether siplizumab, given at the time of liver transplant, can safely prevent the immune system from attacking the new liver. Up to 8 adults with autoimmune hepatitis or primary sclerosing cholangitis will receive two doses. The main goal is to check for serious infections in the first month, while also watching for rejection or disease return over 12 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital
RECRUITINGNew York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells predict herpesvirus danger in transplant patients?
- Can a new drug outperform standard care for a rare liver disease in teens?
- Could a new molecule tame a rare liver disease? early safety trial begins
- Blood test may tame the tightrope walk of transplant drugs
- Muscle quality on MRI may foretell liver transplant success
- Artificial intelligence may help decide who gets a liver first